Skip to main content
. 2020 Mar 18;9(10):3371–3382. doi: 10.1002/cam4.2865

Figure 3.

Figure 3

Survivals and prognostic factors for survivals in 52 patients with refractory/relapsed acute myeloid leukemia treated with CLAM. A‐C, overall survival (OS); D and E, relapse‐free survival (RFS); F and G, event‐free survival (EFS). CLAM, clofarabine, cytarabine, and mitoxantrone